Clinical Trials
75 trialsThe Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
ReAL
Fondazione IRCCS Policlinico San Matteo di Pavia
ITA-WebNet
Fondazione IRCCS Policlinico San Matteo di Pavia
ALACRITY
Alexion Pharmaceuticals, Inc.
ALANIS
GlaxoSmithKline
MED-hATTR
The Cleveland Clinic
BE.Amycon Biobank & Data Registry UZ Leuven
Universitaire Ziekenhuizen KU Leuven
Expanded Access to Venetoclax
AbbVie
Institutional Registry of Rare Diseases
Hospital Italiano de Buenos Aires
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
CARE-Heme
University of Alabama at Birmingham
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Registry for Adults With Plasma Cell Disorders (PCD's)
UNC Lineberger Comprehensive Cancer Center
MICA
Brigham and Women's Hospital
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Memorial Sloan Kettering Cancer Center
A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
Peking University First Hospital
EAR
University Hospital, Essen
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Mayo Clinic
NEXICART-2
Nexcella Inc.
Ixazomib Rollover Study
Takeda
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
University of California, San Francisco
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
xCures
MargheRITA
Advice Pharma Group srl
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Sanguine Biosciences
Daratumumab for Patients With Light Chain Amyloidosis
Nanjing University School of Medicine
IsAMYP
Intergroupe Francophone du Myelome
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders
University Health Network, Toronto
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
University of Tennessee Graduate School of Medicine
Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
The Cleveland Clinic
Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Massachusetts General Hospital
STARR
Weill Medical College of Cornell University
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Peking University First Hospital
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
University of Tennessee Graduate School of Medicine
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
National Cancer Institute (NCI)
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Indiana University
CAST
The Cleveland Clinic
ALF
The Cleveland Clinic
MRD
Boston Medical Center
DUAL
Medical College of Wisconsin
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
University of Athens
CATALYST
University College, London
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Boston Medical Center
Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis
Tufts Medical Center
Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
Tufts Medical Center
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center